Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06704685 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI

Study acronym: RISE
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 26, 2024 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This study is a prospective, randomized, placebo-double-blind, multicenter clinical trial. The purpose of this study is to investigate whether "butylphthalide +PCI" combined treatment mode on the basis of traditional drug therapy could reduce myocardial infarct size, improve cardiac function and long-term prognosis of patients with acute myocardial infarction, and verify the drug safety of butylphthalide in the treatment of STEMI within the window period of 12 hours.
Trial Details
NCT Number NCT06704685
Lead Sponsor Xiangya Hospital of Central South University
Collaborators: CSPC Pharmaceutical Group Limited
Conditions
(from sponsor)		 ST-segment Elevation Myocardial Infarction (STEMI)
Related terms ST Elevation Myocardial Infarction
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov